Value, Affordability, and Decision Making
Efficient decisions about allocating health care budgets require assessment of the effects of health care interventions and the value for money they provide. Decision-making processes leading to funding decisions should be structured and evidence-based.
Around The World in HTAs: France – Three Core HTA Values
12 March 2026
In the latest edition of our Insights series, Around the World in HTAs, we explore the HTA system in France. A special thanks to Salah Ghabri for his valuable support to write this note.
Novel devices: optimising drug delivery in multiple myeloma
9 December 2025
Biologics: Driving innovation in the treatment of multiple myeloma Biological medicines (biologics) have transformed the treatment landscape of multiple myeloma and cancer as a whole. The…
A global landscape analysis of access to tumour-agnostic therapies
1 December 2025
Tumour-agnostic (TA) therapies represent a paradigm shift in oncology by targeting molecular alterations regardless of tumour histology.
Achieving Accelerated Patient Access to Cancer Care in Europe
3 November 2025
OHE developed the Accelerated Patient Access to Cancer Care in Europe (APACE) framework through a structured, multidisciplinary stakeholder engagement process.
The value of cell and gene therapies to the UK economy
20 October 2025
Cell and gene therapies (CGTs) are moving rapidly from specialist trials to routine care: more than thirty products are already licensed worldwide and over two thousand are in clinical development.
The broader economic benefits of COVID-19 vaccination
13 October 2025
Extending COVID-19 vaccination eligibility to working-age adults could nearly triple the benefits to national economies.
Around the World in HTAs: Saudi Arabia – Navigating the healthcare and HTA landscape
24 September 2025
Saudi Arabia’s healthcare system is undergoing a significant transformation, driven by ambitious structural, regulatory and financial reforms outlined in Vision 2030. These changes are creating a dynamic environment for health technologies and their pathway to market.
Around the world in HTAs: China – From fragmentation to function
2 September 2025
In this Insights series, Around the World in HTAs, we shed light on HTA around the world. In this edition Yawen Jiang, Meng Li and Claud Theakston take us to China.
How Widely Are QALYs Used in OECD Countries? A Snapshot of International Practices
11 June 2025
As healthcare systems strive to allocate resources efficiently, the use of economic evaluation metrics like Quality-Adjusted Life Years (QALYs) has become increasingly important.